Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents

Hematopoietic Stem Cell Transplant in Elderly Patients: Experience from a Tertiary Care Centre in Northern India

“…In NMDP and CIBMTR data there was no difference in rates of nonrelapse mortality, grade 2-4 GVHD, chronic GVHD, or relapse in patient less than or more than 60 years [3]. Similarly, age at transplantation has no prognostic significance on outcome in autologous HSCT [4]. Our results also showed that age alone has no impact on outcome in elderly patients undergoing stem cell transplantation.…”

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)

“…[32] However, a number of retrospective single-center studies have indicated that auto-SCT may be safe and effective for selected elderly patients. [3,[33][34][35][36][37][38] The cohort was divided into three groups: 18-59 years old (n = 5818), 60-69 years old (n = 4666), and more than 69 years old (n = 946). After a median follow-up of 3 years, median OS was not reached for any cohort.…”

Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age

“…Performance status and HCT-CI are better correlated with survival than age [17]. In the modern era of myeloma therapy, novel agent-based induction that preserves performance status and allows for stem cell harvest will perhaps result in greater proportion of older patients being able to avail the benefits of autologous HCT in myeloma [18]. An approach of early stemcell harvest and HCT after induction is preferred in older Editorial Michaelis, Hamadani & Hari patients for whom a delayed HCT at relapse may not be a practical option due to changes in health status.…”